Sanity Group is a Berlin-based cannabis company that aims to improve people's quality of life through the utilization of cannabinoids. The company operates in the medical, consumer health, and scientific sectors, focusing on pharmaceuticals, medical products, and consumer goods. Sanity Group encompasses various subsidiaries, including Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing), and This Place (natural cosmetics).
In September 2022, Sanity Group successfully closed a USD 37.6 million Series B financing round, marking Europe's largest cannabis investment round to date. This funding was led by BAT Group, with continued support from existing investors such as Redalpine and Casa Verde Capital, bringing the total funds raised by the company to over USD 100 million. The new investment will fuel Sanity Group's growth, enable European expansion, and strengthen research and development activities.
Near Frankfurt am Main, Sanity Group operates a production and processing facility for cannabis extracts. In June 2024, Organigram Holdings Inc., a Canadian cannabis producer, took a minority stake in Sanity Group through a USD 21 million investment, with the potential for an additional USD 4.5 million investment via an unsecured convertible note. This investment aims to help Organigram capitalize on the recent legalization of cannabis in Germany, where Sanity Group holds approximately 10% market share in the medical cannabis market.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.